Biodrugs

Papers
(The H4-Index of Biodrugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review207
Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review107
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies92
Outer Membrane Vesicle Vaccine Platforms79
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases74
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network65
Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries51
Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration48
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies47
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study45
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins41
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians33
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout31
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience31
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)30
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry30
Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia30
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study29
Plant-Derived Human Vaccines: Recent Developments28
Treatment with Biologic Drugs in Pediatric Behçet’s Disease: A Comprehensive Analysis of the Published Data27
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland27
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association27
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial27
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options26
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis25
0.24618005752563